

March 14, 2025

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Growth)

**[Updated] Non-Consolidated Financial Results (Japanese GAAP)  
for the Fiscal Year Ended December 31, 2024**

Chiome Bioscience makes some corrections to “Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2024” released on February 13, 2025.

The corrections are underlined as shown on the following pages.

Correction on page 5

1. Overview of Operating Results

(3) Overview of Cash Flows in the Fiscal Year Under Review

[Before correction]

(Cash flows from operating activities)

The funds used in operating activities amounted to ¥1,000,664 thousand. The main reason for this was the recording of a loss before tax.

(Cash flows from financing activities)

The funds acquired as a result of financing activities amounted to ¥ 1,738,390 thousand. This was mainly due to the issue of shares resulting from the exercise of stock acquisition right.

[After correction]

(Cash flows from operating activities)

The funds used in operating activities amounted to ¥1,000,695 thousand. The main reason for this was the recording of a loss before tax.

(Cash flows from financing activities)

The funds acquired as a result of financing activities amounted to ¥ 1,738,421 thousand. This was mainly due to the issue of shares resulting from the exercise of stock acquisition right.

Correction on page 9

3. Financial Statements

(2) Statements of Income

【Details of Cost of Sales】

[Before correction]

Category	note	Fiscal Year Ended Dec. 31, 2023 (Jan. 1, 2023 to Dec. 31, 2023)		Fiscal Year Ended Dec. 31, 2024 (Jan. 1, 2024 to Dec. 31, 2024)	
		Amount (Thousand yen)	Proportion of cost of sales (%)	Amount (Thousand yen)	Proportion of cost of sales (%)
I Cost of materials	* 1	118,634	41.7	117,980	33.9
II Labor costs		83,600	29.4	76,755	22.0
III Expenses		82,126	28.9	153,522	44.1
Total manufacturing costs		284,361	100.0	348,258	100.0
Opening balance of work-in-progress under inventories		1,151		1,644	
Total		285,513		<u>349,903</u>	
Closing balance of work-in-progress under inventories		1,644		1,944	
Cost of sales		283,869		347,957	

[After correction]

Category	note	Fiscal Year Ended Dec. 31, 2023 (Jan. 1, 2023 to Dec. 31, 2023)		Fiscal Year Ended Dec. 31, 2024 (Jan. 1, 2024 to Dec. 31, 2024)	
		Amount (Thousand yen)	Proportion of cost of sales (%)	Amount (Thousand yen)	Proportion of cost of sales (%)
I Cost of materials	* 1	118,634	41.7	117,980	33.9
II Labor costs		83,600	29.4	76,755	22.0
III Expenses		82,126	28.9	153,522	44.1
Total manufacturing costs		284,361	100.0	348,258	100.0
Opening balance of work-in-progress under inventories		1,151		1,644	
Total		285,513		<u>349,902</u>	
Closing balance of work-in-progress under inventories		1,644		1,944	
Cost of sales		283,869		347,957	

Correction on page 12

3. Financial Statements

(4) Statements of Cash Flows

[Before correction]

	Thousand yen	
	Fiscal Year Ended Dec. 31, 2023 (Jan. 1, 2023 to Dec. 31, 2023)	Fiscal Year Ended Dec. 31, 2024 (Jan. 1, 2024 to Dec. 31, 2024)
Cash flows from operating activities		
Loss before income taxes	(1,215,008)	(1,017,536)
Depreciation and amortization	1,203	1,166
Subsidy income	—	(28,011)
Decrease (increase) in notes and accounts receivable-trade	32,024	32,130
Decrease (increase) in inventories	7,371	17,936
Decrease (increase) in advance payments	4,679	(15,195)
Decrease (increase) in consumption taxes refund receivable	4,520	(2,179)
Increase (decrease) in notes and accounts payable-trade	5,869	(10,538)
Increase (decrease) in accounts payable-other	46,151	20,763
Increase (decrease) in accrued expenses	(971)	3,969
Other, net	42,928	4,519
Subtotal	<u>(1,071,232)</u>	<u>(992,974)</u>
Interest income received	16	182
Interest paid	(2,069)	(2,865)
Proceeds from subsidy income	9,100	—
Income taxes paid	(5,010)	(5,010)
Income taxes refund	3	2
Net cash used in operating activities	<u>(1,069,192)</u>	<u>(1,000,664)</u>
Cash flows from investing activities		
Proceeds from sale of property, plant and equipment	173	—
Net cash used in investing activities	<u>173</u>	<u>—</u>
Cash flows from financing activities		
Proceeds from short-term borrowings	107,000	(9,500)
Proceeds from issuance of common shares	554,515	1,748,473
Proceeds from issuance of subscription rights to shares	5,787	(582)
Other, net	(0)	—
Net cash provided by (used in) financing activities	<u>667,303</u>	<u>1,738,390</u>
Net decrease in cash and cash equivalents	<u>(401,715)</u>	<u>737,725</u>
Cash and cash equivalents as of the beginning of the year	<u>1,727,270</u>	<u>1,325,554</u>
Cash and cash equivalents as of the end of the year	<u>1,325,554</u>	<u>2,063,280</u>

[After correction]

	Thousand yen	
	Fiscal Year Ended Dec. 31, 2023 (Jan. 1, 2023 to Dec. 31, 2023)	Fiscal Year Ended Dec. 31, 2024 (Jan. 1, 2024 to Dec. 31, 2024)
Cash flows from operating activities		
Loss before income taxes	(1,215,008)	(1,017,536)
Depreciation and amortization	1,203	1,166
Subsidy income	—	(28,011)
Decrease (increase) in notes and accounts receivable-trade	32,024	32,130
Decrease (increase) in inventories	7,371	17,936
Decrease (increase) in advance payments	4,679	(15,195)
Decrease (increase) in consumption taxes refund receivable	4,520	(2,179)
Increase (decrease) in notes and accounts payable-trade	5,869	(10,538)
Increase (decrease) in accounts payable-other	46,151	20,763
Increase (decrease) in accrued expenses	(971)	3,969
Other, net	42,928	4,488
Subtotal	<u>(1,071,232)</u>	<u>(993,005)</u>
Interest income received	16	182
Interest paid	(2,069)	(2,865)
Proceeds from subsidy income	9,100	—
Income taxes paid	(5,010)	(5,010)
Income taxes refund	3	2
Net cash used in operating activities	<u>(1,069,192)</u>	<u>(1,000,695)</u>
Cash flows from investing activities		
Proceeds from sale of property, plant and equipment	173	—
Net cash used in investing activities	<u>173</u>	<u>—</u>
Cash flows from financing activities		
Proceeds from short-term borrowings	107,000	(9,500)
<u>Proceeds from issuance of bonds</u>	<u>—</u>	<u>250,000</u>
<u>Redemption of bonds</u>	<u>—</u>	<u>(250,000)</u>
Proceeds from issuance of common shares	554,515	1,749,912
Proceeds from issuance of subscription rights to shares	5,787	—
<u>Payments for issuance of subscription rights to shares</u>	<u>—</u>	<u>(582)</u>
<u>Payments for purchase of treasury subscription right to shares</u>	<u>—</u>	<u>(1,408)</u>
Other, net	(0)	—
Net cash provided by (used in) financing activities	<u>667,303</u>	<u>1,738,421</u>
Net decrease in cash and cash equivalents	<u>(401,715)</u>	<u>737,725</u>
Cash and cash equivalents as of the beginning of the year	<u>1,727,270</u>	<u>1,325,554</u>
Cash and cash equivalents as of the end of the year	<u>1,325,554</u>	<u>2,063,280</u>

**【Inquiries】**

Chiome Bioscience Inc. Investor Relations

Email : ir@chiome.co.jp